Sector Experts

Subscribe to
Streetwise Reports

Ask this Expert

Companies Commented On

Stephen Dunn

LifeTech Capital

Image: Stephen Dunn

LifeTech Capital President and Senior Managing Director Stephen Dunn was previously the managing director of Life Sciences Research at Jesup & Lamont, as well as director of research for Dawson James Securities and director of Life Sciences at Cabot Adams venture capital group. He has held management positions in business development, finance and operations, having worked in more than 25 countries in North America, Europe and the Far East with biomedical companies including Beckman Coulter, Coulter, Cordis (Johnson & Johnson) and Telectronics (St. Jude Medical), as well as several smaller companies. With more than 25 years in the global biomedical industry, Dunn has negotiated numerous intellectual property licenses, product development agreements, venture funding, mergers and acquisitions and joint ventures. Dunn is a five-star biotechnology analyst on StarMine and has appeared in both the financial and scientific media, including The Wall Street Journal, CNN, Newsweek, Forbes, Nightly Business Report, Nature Biotechnology, The Scientist, BioWorld and many other media outlets. He is a frequent speaker and panel member for many financial, medical and venture capital events.




Recent Interviews

Immuno-Oncology Promises Continued Wealth and Health: LifeTech Capital's Stephen Dunn (2/19/15) Immuno-oncologyŚdisabling cancer's defenses so that a patient's own immune system can seek it out and destroy itŚtook center stage in the drug development world in 2014. Stephen Dunn of LifeTech Capital believes that preeminence will continue in 2015, bolstered by new drug approvals, new targets and new combination immunotherapies that increase potency. In this interview with The Life Sciences Report, Dunn outlines how companies large and small are leveraging these therapies, and where investors should look for opportunity in the sector.

ASCO Abuzz About Immunotherapies: A Preview of the Latest in Cancer Therapy from Stephen Dunn (5/28/14) Working in what is arguably the hottest sector in the drug development industry, biotech researchers continue to ferret out cancer's secrets. The premier event for those in the field is the American Society of Clinical Oncology annual meeting, taking place in Chicago from May 30 to June 1. Participants have submitted abstracts for promising therapies in advance of the conference, profiling new compounds that could lead to better outcomes for patients and bolster the health of investment portfolios. In this interview with The Life Sciences Report, LifeTech Capital's Stephen Dunn walks us through some of the highlights.

Can Stem Cells Regenerate Your Portfolio? Stephen Dunn Says Yes (9/27/12) Once the subject of intense political debate, stem cell therapies may soon be a therapeutic mainstay of healthcare. In this exclusive interview with The Life Sciences Report, LifeTech Capital's President and Senior Managing Director of Research Stephen Dunn explores the history of stem cell therapy and discusses companies that are reviving this "old" technique for profit.

Recent Quotes

"CBMG is acquiring CD40LGVAX, a lung adenocarcinoma vaccine." (6/10/15) Cellular Biomedicine Group Inc. - Stephen Dunn, LifeTech Capital Moreá>

"CBMG's fundamentals have gotten stronger over the past five weeks." (5/6/15) Cellular Biomedicine Group Inc. - Stephen Dunn, LifeTech Capital Moreá>

"Investors should keep a close eye on CBMG during 2015." (2/19/15) Cellular Biomedicine Group Inc. - The Life Sciences Report Interview with Stephen Dunn Moreá>

"We foresee significant upside potential for CBMG and are increasing our target price." (2/17/15) Cellular Biomedicine Group Inc. - Stephen Dunn, LifeTech Capital Moreá>

"CBMG is significantly undervalued as it should see added value in 2015 and beyond." (2/2/15) Cellular Biomedicine Group Inc. - Stephen Dunn, LifeTech Capital Moreá>

"STEM initiated a controlled Phase 2 trial in cervical SCI patients." (11/17/14) StemCells Inc. - Stephen Dunn, LifeTech Capital Moreá>

"STEM's Pathway will evaluate transplanting stem cells in SCI patients." (10/7/14) StemCells Inc. - Stephen Dunn, LifeTech Capital Moreá>

"We remain enthusiastic about STEM's science and clinical prospects." (9/18/14) StemCells Inc. - Stephen Dunn, LifeTech Capital Moreá>

more comments

"STEM continues to build on its strong management team." (7/7/14) StemCells Inc. - Stephen Dunn, LifeTech Capital Moreá>

"It appears that STEM's HuCNS-SC is disease modifying in dry AMD." (6/19/14) StemCells Inc. - Stephen Dunn, LifeTech Capital Moreá>

"STEM adds to its executive team, one of the strongest in the space." (6/17/14) StemCells Inc. - Stephen Dunn, LifeTech Capital Moreá>

"There will be no doubt that CPXX's CPX-351 is superior to current first-line, standard-of-care therapy." (5/28/14) Celator Pharmaceuticals Inc. - The Life Sciences Report Interview with Stephen Dunn Moreá>

"ATNM is developing Iomab-B for acute myeloid leukemia patients undergoing a bone marrow transplant." (5/28/14) Actinium Pharmaceuticals Inc. - The Life Sciences Report Interview with Stephen Dunn Moreá>

"STEM's results on thoracic SCI patients are very significant." (5/20/14) StemCells Inc. - Stephen Dunn, LifeTech Capital Moreá>

"STEM completed enrollment in its SCI Phase 1/2 clinical trial." (4/17/14) StemCells Inc. - Stephen Dunn, LifeTech Capital Moreá>

"STEM remains one of the most advanced players in the stem cell space." (3/24/14) StemCells Inc. - Stephen Dunn, LifeTech Capital Moreá>

"CIRM's $19M funding for HuCNS-SC in Alzheimer's disease validates STEM's research." (1/10/14) StemCells Inc. - Stephen Dunn, LifeTech Capital Moreá>

"STEM's strong management team and strong science continues to be successfully validated." (1/2/14) StemCells Inc. - Stephen Dunn, LifeTech Capital Moreá>

fewer comments


Due to permission requirements, not all quotes are shown.